PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, — Glendale, California

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, is a clinical research site located in Glendale, California, United States 91206.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, has participated in 1 clinical trials.

Therapeutic areas: Schizophrenia Disorders.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,?

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, conducted?

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, has 1 clinical trials on record. Their work covers Schizophrenia Disorders.

Is PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, accredited by Crixeo Health?

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140, has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.